The Translational Therapeutics Core (TTC) is accelerating preclinical development of new therapeutics for Alzheimer’s disease (AD) and AD-related dementia (ADRD) through human target validation. This includes supplying the following clinically-characterized samples from patients and matched controls.
- Human brain tissue (both frozen and fixed)
- Cerebrospinal fluid
Applications for TTC tissue are welcomed from researchers working on projects related to putative therapeutic processes for AD / ADRD. Applications are evaluated by the team below. Successful applicants are guided through pilot proof of principle studies, followed by definitive highly-powered studies. Modest funds are available to support the translational studies in the scientist’s home lab, if requested.
The TTC is located at University Hospitals (UH) Cleveland Medical Center, and is directed by Andrew A. Pieper, MD PhD, who also serves as Director of the Neurotherapeutics Center of the Harrington Discovery Institute of UH. The connection to the Harrington Discovery Institute also offers opportunity for guidance and support in drug development for AD/ADRD for TTC-supported investigators.
The TTC works closely with the Neuropathology Core, the Biomarker Core, and the Research Education Component of the CADRC. Starting in 2021, the TTC will also identify and financially support an annual TTC-REC fellow.
Researchers may request tissue through contacting TTC@ClevelandADRC.org
Andrew A. Pieper, MD PhD, Translational Therapeutics Core Leader
Coral J. Cintrón-Pérez, M.B.A., TTC coordinator
James Leverenz, MD, Co-Investigator
Jeffrey L. Cummings, MD, Co-Investigator
Babak Tousi, MD, Co-Investigator
Alan J. Lerner, MD, Co-Investigator